key: cord-0299917-u2q66ok3
authors: Kirchenwitz, Marco; Stahnke, Stephanie; Prettin, Silvia; Borowiak, Malgorzata; Birchmeier, Carmen; Rottner, Klemens; Stradal, Theresia E.B.; Steffen, Anika
title: SMER28 attenuates PI3K/mTOR signaling by direct inhibition of PI3K p110 delta
date: 2021-12-13
journal: bioRxiv
DOI: 10.1101/2021.12.10.471916
sha: a3285cbf75a2f5b87257ca1e8ed76d54b8ec0048
doc_id: 299917
cord_uid: u2q66ok3

SMER28 (Small molecule enhancer of Rapamycin 28) is an autophagy-inducing compound functioning by a hitherto unknown mechanism. Here we confirm its autophagy-inducing effect by assessing classical autophagy-related parameters. Interestingly, we also discovered several additional effects of SMER28, including growth retardation and reduced G1 to S phase progression. Most strikingly, SMER28 treatment led to a complete arrest of receptor tyrosine kinase signaling, and consequently growth factor-induced cell scattering and dorsal ruffle formation. This coincided with a dramatic reduction of phosphorylation patterns of PI3K downstream effectors. Consistently, SMER28 directly inhibited PI3Kδ and to a lesser extent p110γ. The biological relevance of our observations was underscored by interference of SMER28 with InlB-mediated host cell entry of Listeria monocytogenes, which requires signaling through the prominent receptor typrosine kinase c-Met. This effect was signaling-specific, since entry of unrelated, gram-negative Salmonella Typhimurium was not inhibited.

note, most of the dorsal ruffles still formed in SMER28-treated cells were much smaller and/or 186 not completely circularly closed. Collectively, these data reveal that SMER28 severely impairs 187 signaling downstream of RTKs such as HGF and PDFG. 188 SMER28 directly targets PI3K subunits gamma and delta 189 signal transmission, we addressed whether SMER28 specifically affects kinase activity 214 upstream of mTOR. Surprisingly, we found that SMER28 mildly reduced the levels of pTyr607 215 PI3K, whereas rapamycin did not change these levels, as expected ( Figure 5A , B). The 216 oncogene AKT is an indirect downstream effector of PI3K and phosphorylated by mTORC2 at 217 Ser473 (37, 38) and by PDK1 at Thr308 (39). We thus quantitatively analyzed both 218 phosphorylation sites of AKT and found, to our surprise, strongly reduced levels of Ser473-219 AKT phosphorylation by SMER28 (38% and 75% reduction with 50 µM and 200 µM SMER28, 220 respectively) ( Figure 5A , B). In contrast, rapamycin increased p-Ser473-AKT almost twofold 221 ( Figure 5A , B), which has been described to occur by mTORC1 inhibition (40, 41). These data 222 thus corroborate the mTORC1-independent mode of action of SMER28 (19). Interestingly, the 223 levels of phosphorylated AKT at residue Thr308 were reduced by more than 50% by 200 µM 224 SMER28, and to much lesser extent with 50 µM SMER28 ( Figure 5A , B), indicating that it acts 225 on AKT phosphorylation indirectly and thus independent of its specific kinases mTORC2 and 226 PDK1. We tested therefore whether SMER28 compromises PI3K function directly using an in 227 vitro kinase assay. The active enzyme PI3K converts PIP2 to PIP3, which can be quantitatively 228 assessed by adding biotinylated PIP3 (B-PIP3) as tracer. Class I PI3Ks comprise four different 229 members that are differentiated by their catalytic subunits p110 alpha, beta, gamma and delta 230 (5). The ubiquitously expressed subunits alpha and beta were markedly inhibited with 200 µM 231 SMER28, but only mildly affected with 50 µM of the compound. Notably however, PI3K activity 232 exerted by the p110 delta subunit was eliminated with 200 µM SMER28 and almost entirely 233 suppressed (by 87%) with 50 µM SMER28 ( Figure 5C ). The activity of the gamma subunit was 234 inhibited more moderately, i.e. by 43% and 86% with 50 µM and 200 µM SMER28, respectively 235 ( Figure 5C ). To confirm the mode of action of SMER28 in a cellular assay, and to assess the 236 relevance of this drug in in vivo applications, we investigated the effect of SMER28 on Listeria 237 invasion. Listeria monocytogenes is a gram-positive, bacterial pathogen that can cause 238 abortions and illnesses such as meningitis. Listeria invades host cells by binding of its surface 239 and/or secreted factors, internalin A (InlA) and InlB to the host cell receptors cadherin-1/E-240 cadherin and c-Met/HGFR, respectively. As the InlA-E-cadherin interaction is restricted to the 241 human system (42), internalin-specific entry into murine cells depends entirely on the InlB-Met 242 pathway. Met/HGFR is widely expressed; so signaling can be induced by binding of its natural 243 ligand HGF in various cell lines (see also Figure 4 ) as well as by binding of bacterial InlB, 244 known to involve PI3K activation (43-46). We therefore addressed the invasion capability of 8 reduced Listeria wildtype invasion by almost 90%, while 200 µM SMER28 completely 248 abolished entry. Wortmannin and LY294002, two different pan-PI3K inhibitors, reduced Listeria 249 invasion by only 39% and approx. 75%, respectively ( Figure 6A , B). The differences of effects 250 of both inhibitors could be due to the poor stability of wortmannin in solution (47). Additional 251 effects seen with these inhibitors on the invasion of Internalin A/B deletion mutants (Listeria 252 InlA/B) indicated a role for PI3K on non-specific, i.e. InlB-independent entry ( Figure 6A, C) . 253

This conclusion was corroborated by comparing Listeria wildtype entry (with or without PI3K 254 inhibition) into cells with or without genetic elimination of the HGF/InlB-receptor (c-Met). 255

Results from c-Met-KO cells ( Figure 6C ) essentially phenocopied Listeria InlA/B data in 256 wildtype fibroblasts ( Figure 6A , B). Moreover, wortmannin was again less effective in control 257 and c-Met KO cells than SMER28 at both concentrations employed ( Figure 6C ). These data 258 demonstrated that SMER28 has robust effects on InlB-mediated Listeria invasion known to 259 involve PI3K function in different cells lines. By contrast, gram-negative Salmonella enterica 260 Serovar Typhimurium causing food-borne diarrhea invade host cells largely independently of 261 class I PI3 kinases (48, 49). We thus also explored the invasion capacity of Salmonella in the 262 presence and absence of SMER28. Strikingly, SMER28 treatments did not significantly affect 263 the invasion capacity of Salmonella into NIH/3T3 fibroblasts ( Figure 6D ), similar to what was 264 found with LY294002 ( Figure 6E ). To exclude that the compound has a harmful effect on 265

Listeria itself, we performed growth curves of Listeria in bacterial growth and cell culture 266 medium supplemented with 50 µM and 200 µM SMER28, respectively, or gentamycin as a 267 classical antibiotic as control, and compared these growth curves to DMSO control. As shown 268 in Figure 6F , none of the SMER28 conditions led to an adverse growth affect, while gentamycin 269 effectively inhibited Listeria growth, excluding that the reduced Listeria invasion rates observed 270 above are due to toxic effects of SMER28 on the bacteria. 271

Together, our data reveal a specific inhibition of class I PI3 kinases by SMER28 with differential 272 activity towards respective p110 subunits, in particular p110 delta. 273 274

The initial reports describing an mTOR-independent, autophagy-inducing potential of SMER28 276 left an important question unanswered: what is the direct target of SMER28 mediating this 277 activity (19)? While we were able to confirm a modest, autophagy-inducing effect of SMER28 278 here, we discovered, to our surprise, that SMER28 acts on the RTK signaling axis by directly 279 binding to and inhibiting PI3K. More specifically, SMER28 exhibits its strongest inhibitory 280 activity on functional class I PI3K complexes comprising the catalytic subunit p110 delta. We 9 identification of this drug as PI3K inhibitor. It remains to be discovered whether SMER28 may 283 have additional, biological targets. The enzymatic activity of PI3K is connected to essential 284 cellular processes such as cell growth, cell cycle regulation and cell migration (50). In this 285 study, we are able to connect several cell biological phenomena to SMER28-mediated in vitro 286 inhibition of PI3K. We show that SMER28 has a cytostatic effect that is accompanied by low 287 cytotoxicity, highlighting the role of PI3K as a growth factor/nutrient sensor, since inhibition of 288 PI3K in malignant cells is more commonly cytostatic than cytotoxic (51). Moreover, we find that 289 SMER28 has immediate effects on dynamic changes of the cytoskeleton such as dorsal ruffle 290 formation or long-lasting effects like cell scattering, both of which require cytoskeletal 291 rearrangements (32); such types of plasticity changes are key characteristics of cancer cells. 292

Aberrant PI3K signaling is commonly occurring in many types of cancers. Any type of 293 misregulation of PI3K activity may lead to hyperactivation of the pathway, either by 294 hyperactivating mutations of the enzyme itself, increased expression, increased PI3K copy 295 numbers or loss of PI3K suppressors such as its direct antagonist PTEN. This often contributes 296 to the development of diseases, such as cancer, but also immunological or neurological 297 disorders as well as diabetes (5, 6, 18, 51). Thus, the development of therapeutics for 298 treatments based on PI3K has been driven forward with much effort. These activities resulted 299 in identification of a number of drugs that can be subdivided into dual PI3K/mTOR inhibitors, 300 pan-PI3K inhibitors and isoform-specific inhibitors (16). Class I PI3K comprises four different 301 members that are differentiated by their catalytic subunit p110. PI3K and PI3K are 302 expressed ubiquitously, while PI3K and PI3K are enriched in the hematopoietic system (5). 303 B-cell malignancies such as multiple myeloma (MM), chronic lymphocytic leukemia (CLL) and 304 indolent Non-Hodgkin Lymphoma (iNHL) are strikingly dependent on PI3K activity (51, 52). 305

Hence, drugs specifically targeting this enzyme were in demand for treatment of these 306 lymphomas. The first PI3K-specific inhibitor idelalisib (CAL-101) was approved by the FDA in 307 2014 (53-55). Notably, idelalisib induces autophagy (52). Unfortunately, idelalisib-treatment of 308 relapsed CLL is accompanied by hepatotoxicity (56), which is hypothesized to be an off-target 309 effect based on its structure. Subsequently-developed PI3K-selective inhibitors such as 310 parsaclisib and umbralisib were thus modified but based on the chemical structure of idelalisib 311 (57). Although the chemical structure of SMER is known (19), the identification of the structural 312 basis SMER28 binding to p110 delta will certainly help to understand the exact mechanism of 313 inhibition. Moreover, it will be interesting to address whether the low cellular cytotoxicity of 314 SMER28 observed here could be translated into human application. Strikingly, the systemic 315 treatment of mice with SMER28 (58) fitted the low cytotoxicity that had been reported earlier 316 (59, 60) and could be confirmed here, thus constituting promising insight for future, organismic 317 application. Specifically, our findings imply that SMER28 might be an applicable drug for 318 treatment of B-cell Non-Hodgkin-lymphoma. In addition to this, the PI3K signaling pathway For Listeria gentamycin protection assays, the overnight culture was directly harvested by 423 centrifuging at 3,000 x g for 3 min and the bacterial density adjusted to a MOI of 100 in DMEM. 424

Infection of respective cell lines was performed essentially as described above, except that 425 after incubation for 60 min, cells were washed once with PBS before addition of 50 µg/ml 426 gentamycin in DMEM for 2 hours. Cells were then washed three times with PBS and lysed with 427 0.5% Triton X-100 in PBS for 5 min at room temperature. Lysates of all conditions were 428 harvested on ice, and serial dilutions in PBS plated onto agar plates, followed by incubation at 429 37°C overnight. Colonies were then counted with an automatic colony counter (Scan4000, 

The PI3K

PI3K in cancer: divergent roles of isoforms, modes 594 of activation and therapeutic targeting

Autophagy is a major metabolic regulator involved 596 in cancer therapy resistance

AMBRA1 links autophagy to cell proliferation and tumorigenesis by promoting c-Myc 599 dephosphorylation and degradation

Tumor-suppressor function 601 of Beclin 1 in breast cancer cells requires E-cadherin

AMPK and mTOR regulate autophagy through 665 direct phosphorylation of Ulk1

mTORC1 667 phosphorylation sites encode their sensitivity to starvation and rapamycin

Akt/PKB by the rictor-mTOR complex

SIN1/MIP1 maintains 672 rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity

Cdc42 and distinct and common pathways

Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, 699 quercetin, myricetin, and staurosporine

Akt by the bacterial inositol phosphatase, SopB, is wortmannin insensitive

Multiple 704 host kinases contribute to Akt activation during Salmonella infection

Cracking the context-specific PI3K signaling code

Targeting PI3K in Cancer: Impact on

Cancer Discov. 710 decreases levels of Abeta and APP-CTF via Atg5-dependent autophagy pathway

Phosphoinositide-737 3 kinase-Akt pathway controls cellular entry of Ebola virus

3D culture 741 conditions support Kaposi's sarcoma herpesvirus (KSHV) maintenance and viral spread in 742 endothelial cells

Epstein-Barr Virus Susceptibility in Activated PI3Kdelta